Sirolimus-eluting coronary stents: novel devices for the management of coronary artery disease.

Angela Cheng-Lai, William H. Frishman

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Despite major technological advances in the practice of percutaneous coronary intervention, restenosis of the treated arteries remains a challenge for many interventional cardiologists. Sirolimus is a macrolide antibiotic with potent antifungal, immunosuppressive, and antimitotic activities. Sirolimus inhibits in-stent restenosis via 2 major mechanisms of action: by blocking the process of neointimal hyperplasia by inhibiting smooth muscle cell proliferation and by inhibiting inflammatory cell activity. In pivotal clinical trials, the sirolimus-eluting stent has demonstrated significant improvements in angiographic and clinical outcomes compared with bare metal stents in patients with de novo lesions in native coronary arteries. Since the systemic exposure of sirolimus in patients who received the drug-eluting stent is minimal, adverse effects resulting from systemic exposure of sirolimus are unlikely to occur. Further studies are needed to determine the safety and effectiveness of sirolimus-eluting stents in patients with more complex coronary artery lesions. In addition, the long-term safety, efficacy, and cost-effectiveness of this novel drug-eluting device will need to be established in ongoing clinical trials. This review article focuses on the pharmacology as well as clinical studies of the sirolimus-eluting stent.

Original languageEnglish (US)
Pages (from-to)218-228
Number of pages11
JournalAmerican Journal of Therapeutics
Volume11
Issue number3
StatePublished - May 2004

Fingerprint

Sirolimus
Stents
Coronary Artery Disease
Equipment and Supplies
Coronary Vessels
Clinical Trials
Coronary Restenosis
Antimitotic Agents
Safety
Drug-Eluting Stents
Macrolides
Percutaneous Coronary Intervention
Immunosuppressive Agents
Smooth Muscle Myocytes
Cost-Benefit Analysis
Hyperplasia
Arteries
Metals
Cell Proliferation
Pharmacology

ASJC Scopus subject areas

  • Pharmacology

Cite this

Sirolimus-eluting coronary stents : novel devices for the management of coronary artery disease. / Cheng-Lai, Angela; Frishman, William H.

In: American Journal of Therapeutics, Vol. 11, No. 3, 05.2004, p. 218-228.

Research output: Contribution to journalArticle

@article{3e1d345ffbb44259a37b2a49639640d9,
title = "Sirolimus-eluting coronary stents: novel devices for the management of coronary artery disease.",
abstract = "Despite major technological advances in the practice of percutaneous coronary intervention, restenosis of the treated arteries remains a challenge for many interventional cardiologists. Sirolimus is a macrolide antibiotic with potent antifungal, immunosuppressive, and antimitotic activities. Sirolimus inhibits in-stent restenosis via 2 major mechanisms of action: by blocking the process of neointimal hyperplasia by inhibiting smooth muscle cell proliferation and by inhibiting inflammatory cell activity. In pivotal clinical trials, the sirolimus-eluting stent has demonstrated significant improvements in angiographic and clinical outcomes compared with bare metal stents in patients with de novo lesions in native coronary arteries. Since the systemic exposure of sirolimus in patients who received the drug-eluting stent is minimal, adverse effects resulting from systemic exposure of sirolimus are unlikely to occur. Further studies are needed to determine the safety and effectiveness of sirolimus-eluting stents in patients with more complex coronary artery lesions. In addition, the long-term safety, efficacy, and cost-effectiveness of this novel drug-eluting device will need to be established in ongoing clinical trials. This review article focuses on the pharmacology as well as clinical studies of the sirolimus-eluting stent.",
author = "Angela Cheng-Lai and Frishman, {William H.}",
year = "2004",
month = "5",
language = "English (US)",
volume = "11",
pages = "218--228",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Sirolimus-eluting coronary stents

T2 - novel devices for the management of coronary artery disease.

AU - Cheng-Lai, Angela

AU - Frishman, William H.

PY - 2004/5

Y1 - 2004/5

N2 - Despite major technological advances in the practice of percutaneous coronary intervention, restenosis of the treated arteries remains a challenge for many interventional cardiologists. Sirolimus is a macrolide antibiotic with potent antifungal, immunosuppressive, and antimitotic activities. Sirolimus inhibits in-stent restenosis via 2 major mechanisms of action: by blocking the process of neointimal hyperplasia by inhibiting smooth muscle cell proliferation and by inhibiting inflammatory cell activity. In pivotal clinical trials, the sirolimus-eluting stent has demonstrated significant improvements in angiographic and clinical outcomes compared with bare metal stents in patients with de novo lesions in native coronary arteries. Since the systemic exposure of sirolimus in patients who received the drug-eluting stent is minimal, adverse effects resulting from systemic exposure of sirolimus are unlikely to occur. Further studies are needed to determine the safety and effectiveness of sirolimus-eluting stents in patients with more complex coronary artery lesions. In addition, the long-term safety, efficacy, and cost-effectiveness of this novel drug-eluting device will need to be established in ongoing clinical trials. This review article focuses on the pharmacology as well as clinical studies of the sirolimus-eluting stent.

AB - Despite major technological advances in the practice of percutaneous coronary intervention, restenosis of the treated arteries remains a challenge for many interventional cardiologists. Sirolimus is a macrolide antibiotic with potent antifungal, immunosuppressive, and antimitotic activities. Sirolimus inhibits in-stent restenosis via 2 major mechanisms of action: by blocking the process of neointimal hyperplasia by inhibiting smooth muscle cell proliferation and by inhibiting inflammatory cell activity. In pivotal clinical trials, the sirolimus-eluting stent has demonstrated significant improvements in angiographic and clinical outcomes compared with bare metal stents in patients with de novo lesions in native coronary arteries. Since the systemic exposure of sirolimus in patients who received the drug-eluting stent is minimal, adverse effects resulting from systemic exposure of sirolimus are unlikely to occur. Further studies are needed to determine the safety and effectiveness of sirolimus-eluting stents in patients with more complex coronary artery lesions. In addition, the long-term safety, efficacy, and cost-effectiveness of this novel drug-eluting device will need to be established in ongoing clinical trials. This review article focuses on the pharmacology as well as clinical studies of the sirolimus-eluting stent.

UR - http://www.scopus.com/inward/record.url?scp=3843061402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3843061402&partnerID=8YFLogxK

M3 - Article

C2 - 15133538

AN - SCOPUS:3843061402

VL - 11

SP - 218

EP - 228

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 3

ER -